

**Generic Name:** Vigabatrin

**Therapeutic Class or Brand Name:** Sabril

**Applicable Drugs (if Therapeutic Class):** N/A

**Preferred:** Vigabatrin packets for solution (generic)

**Non-preferred:** Sabril packets for solution, Sabril tablets

**Date of Origin:** 2/1/2013

**Date Last Reviewed / Revised:** 7/7/2023

## PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through III are met)

- I. Documented diagnosis of one of the following conditions A through B AND must meet all criteria listed under applicable diagnosis:
  - A. Refractory complex partial seizures
    1. Documented failure of at least two alternative anti-epileptic drugs for complex partial seizures.
    2. Vigabatrin will be used as adjunctive therapy.
    3. Minimum age requirement: 2 years old.
  - B. Infantile spasms
    1. Age is between one month and two years old.
- II. Treatment is prescribed by or in consultation with a neurologist.
- III. Refer to plan document for the list of preferred products. If requested agent is not listed as a preferred product, must have a documented failure, intolerance, or contraindication to a preferred product(s).

## EXCLUSION CRITERIA

- N/A

## OTHER CRITERIA

- Sabril® should be discontinued if a significant clinical response is not achieved within 3 months of initiation (for treatment of refractory complex partial seizures) and within 2 to 4 weeks of initiation (for treatment of infantile spasms), or if clinical failure is obvious earlier.

## QUANTITY / DAYS SUPPLY RESTRICTIONS

- Up to 180 tablets or packets per 30 days

## APPROVAL LENGTH

- **Authorization:** 3 months
- **Re-Authorization:** 1 year. An updated letter of medical necessity or progress notes showing a significant clinical response has been achieved and documentation that vision is being monitored periodically (or that patient is formally exempted from periodic ophthalmologic assessment).

## APPENDIX

N/A

## REFERENCES

1. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2018;91(2):74-81. doi:10.1212/WNL.0000000000005755
2. Sabril. Prescribing information. Lundbeck; 2021. Accessed July 7, 2023. [https://www.lundbeck.com/upload/us/files/pdf/Products/Sabril\\_PI\\_US\\_EN.pdf](https://www.lundbeck.com/upload/us/files/pdf/Products/Sabril_PI_US_EN.pdf)

**DISCLAIMER:** Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.